Individualizing Periods of Commercial Exclusivity to Control Pricing for Drugs and Biologics
Callie M. Blase, Brandon K. Rouault, Maia B. Zoller, Joshua V. Luff, Emma J. Lerch, Brynn N. Lauterbachq, Mark A. Brown, Joachim Storsberg and Christian Schmidt
DOI : 10.3844/ajisp.2019.19.21
American Journal of Immunology
Volume 15, 2019
The pricing for immunologic agents and antibody-based therapeutics has increased precipitously in recent years. Among the key contributors to price hikes is the static practice of granting commercial exclusivity to innovator drugs and biologics. Herein, we present a mechanism for individualizing periods of commercial exclusivity to control pricing for drugs and biologics.
© 2019 Callie M. Blase, Brandon K. Rouault, Maia B. Zoller, Joshua V. Luff, Emma J. Lerch, Brynn N. Lauterbachq, Mark A. Brown, Joachim Storsberg and Christian Schmidt. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.